Literature DB >> 10700542

Home and hospital treatment of acute seizures in children with nasal midazolam.

P Y Jeannet1, E Roulet, M Maeder-Ingvar, M Gehri, A Jutzi, T Deonna.   

Abstract

Rectal diazepam is widely used in the treatment of acute seizures in children but has some disadvantages. Nasal/sublingual midazolam administration has been recently investigated for this purpose but never at home or in a general paediatric hospital. The aim of this open study was to determine the efficacy, the tolerance and the applicability of nasal midazolam during acute seizures in children both in hospital and at home. We included known epileptic children for treatment at home and all children with acute seizures in the hospital. In all, 26 children were enrolled, 11 at home and 17 in the hospital (including two treated in both locations); only one had simple febrile seizure. They had a total of 125 seizures; 122 seizures (98%) stopped within 10 minutes (average 3.6 minutes). Two patients in the hospital did not respond and in three, seizures recurred within 3 hours. None had serious adverse effects. Parents had no difficulties administering the drug at home. Most of those who were using rectal diazepam found that nasal midazolam was easier to use and that postictal recovery was faster. Among 15 children who received the drug under electroencephalogram monitoring (six without clinical seizures), the paroxysmal activity disappeared in ten and decreased in three. Nasal midazolam is efficient in the treatment of acute seizures. It appears to be safe and most useful outside the hospital in severe epilepsies, particularly in older children because it is easy for parents to use. These data should be confirmed in a larger sample of children. Its usefulness in febrile convulsions also remains to be evaluated. Copyright 1999 European Paediatric Neurology Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10700542     DOI: 10.1053/ejpn.1999.0185

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  15 in total

1.  Management of epilepsy.

Authors:  T Deonna
Journal:  Arch Dis Child       Date:  2005-01       Impact factor: 3.791

2.  Development and characterization of mucoadhesive in situ nasal gel of midazolam prepared with Ficus carica mucilage.

Authors:  Shyamoshree Basu; Amal Kumar Bandyopadhyay
Journal:  AAPS PharmSciTech       Date:  2010-08-04       Impact factor: 3.246

3.  Treatment of acute seizures: is intranasal midazolam a viable option?

Authors:  Lesley K Humphries; Lea S Eiland
Journal:  J Pediatr Pharmacol Ther       Date:  2013-04

Review 4.  The current state of treatment of status epilepticus.

Authors:  Lawrence J Hirsch; Jan Claassen
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 5.  Generalised convulsive status epilepticus: an overview.

Authors:  R Nandhagopal
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

Review 6.  Intranasal delivery of antiepileptic medications for treatment of seizures.

Authors:  Daniel P Wermeling
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

Review 7.  Potential new methods for antiepileptic drug delivery.

Authors:  Robert S Fisher; Jet Ho
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  Intranasal midazolam compared with intravenous diazepam in patients suffering from acute seizure: a randomized clinical trial.

Authors:  Mohsen Javadzadeh; Kourosh Sheibani; Mozhgan Hashemieh; Hedyeh Saneifard
Journal:  Iran J Pediatr       Date:  2012-03       Impact factor: 0.364

9.  Treatment of Convulsive and Nonconvulsive Status Epilepticus.

Authors:  Trudy Pang; Lawrence J Hirsch
Journal:  Curr Treat Options Neurol       Date:  2005-07       Impact factor: 3.972

10.  Nasal and buccal treatment of midazolam in epileptic seizures in pediatrics.

Authors:  Ayşe Ulgey; Recep Aksu; Cihangir Bicer
Journal:  Clin Med Insights Pediatr       Date:  2012-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.